Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
GALT Galectin Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: GALT
Price (delayed)
$2.42
Market cap
$153.17M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.72
Enterprise value
$253.65M
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug belapectin (formerly known as GR-MD-02) is a
Highlights
Galectin Therapeutics's EPS has increased by 5% QoQ and by 2.7% YoY
The company's net income rose by 3.9% QoQ
Galectin Therapeutics's quick ratio has shrunk by 96% YoY and by 84% QoQ
GALT's equity has dropped by 57% year-on-year and by 9% since the previous quarter
Key stats
What are the main financial stats of GALT
Market
Valuations
Earnings
Shares outstanding
63.29M
Market cap
$153.17M
Enterprise value
$253.65M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$40.68M
Net income
-$45.19M
EBIT
-$38.96M
EBITDA
-$38.92M
Free cash flow
-$37.35M
Per share
Balance sheet
Liquidity
EPS
-$0.72
EPS diluted
-$0.72
Free cash flow per share
-$0.59
Book value per share
-$1.8
Revenue per share
$0
TBVPS
$0.15
Total assets
$9.53M
Total liabilities
$121.79M
Debt
$107.92M
Equity
-$113.98M
Working capital
-$101.56M
Debt to equity
-0.95
Current ratio
0.08
Quick ratio
0.07
Net debt/EBITDA
-2.58
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-216.7%
Return on equity
N/A
Return on invested capital
-66.5%
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GALT stock price
How has the Galectin Therapeutics stock price performed over time
Intraday
-26.44%
1 week
76.64%
1 month
87.6%
1 year
0%
YTD
87.6%
QTD
98.36%
Financial performance
How have Galectin Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$40.68M
Net income
-$45.19M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 9% year-on-year but it has grown by 4.1% since the previous quarter
The company's net income rose by 3.9% QoQ
Price vs fundamentals
How does GALT's price correlate with its fundamentals
Growth
What is Galectin Therapeutics's growth rate over time
Valuation
What is Galectin Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Galectin Therapeutics's EPS has increased by 5% QoQ and by 2.7% YoY
GALT's equity has dropped by 57% year-on-year and by 9% since the previous quarter
Efficiency
How efficient is Galectin Therapeutics business performance
GALT's ROIC is down by 23% QoQ but it is up by 5% YoY
The ROA has contracted by 17% YoY and by 15% from the previous quarter
Dividends
What is GALT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GALT.
Financial health
How did Galectin Therapeutics financials performed over time
Galectin Therapeutics's total assets is 92% less than its total liabilities
GALT's current ratio has shrunk by 96% YoY and by 84% QoQ
Galectin Therapeutics's quick ratio has shrunk by 96% YoY and by 84% QoQ
The debt is 195% more than the equity
GALT's equity has dropped by 57% year-on-year and by 9% since the previous quarter
The debt has grown by 31% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.